Jazz Pharmaceuticals (JAZZ) Given “Buy” Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report released on Sunday morning. They currently have a $200.00 price target on the specialty pharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on JAZZ. BMO Capital Markets reaffirmed a buy rating and issued a $196.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, September 20th. Mizuho lifted their price objective on shares of Jazz Pharmaceuticals from $144.00 to $150.00 and gave the stock a neutral rating in a research note on Tuesday, December 5th. Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 28th. They issued a neutral rating and a $165.00 price objective on the stock. B. Riley reaffirmed a buy rating and issued a $206.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 5th. Finally, Royal Bank Of Canada reaffirmed a buy rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $181.28.

Shares of Jazz Pharmaceuticals (NASDAQ JAZZ) traded up $4.14 on Friday, hitting $138.97. 544,900 shares of the stock traded hands, compared to its average volume of 507,108. The firm has a market cap of $8,331.32, a PE ratio of 17.44, a P/E/G ratio of 0.90 and a beta of 0.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94. Jazz Pharmaceuticals has a 12 month low of $101.37 and a 12 month high of $163.75.

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total transaction of $150,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Iain Mcgill sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the transaction, the senior vice president now directly owns 28,383 shares in the company, valued at $3,786,859.86. The disclosure for this sale can be found here. Insiders have sold 10,352 shares of company stock worth $1,417,763 over the last ninety days. 4.30% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. World Asset Management Inc lifted its stake in Jazz Pharmaceuticals by 1.9% in the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock valued at $224,000 after acquiring an additional 27 shares during the last quarter. Profund Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 1.3% in the second quarter. Profund Advisors LLC now owns 2,915 shares of the specialty pharmaceutical company’s stock worth $453,000 after buying an additional 38 shares during the last quarter. Toronto Dominion Bank lifted its stake in shares of Jazz Pharmaceuticals by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 81 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 0.5% in the second quarter. Advisors Asset Management Inc. now owns 17,882 shares of the specialty pharmaceutical company’s stock worth $2,781,000 after buying an additional 86 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 4.0% in the second quarter. Victory Capital Management Inc. now owns 3,410 shares of the specialty pharmaceutical company’s stock worth $530,000 after buying an additional 132 shares during the last quarter. Hedge funds and other institutional investors own 91.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/12/11/jazz-pharmaceuticals-jazz-given-buy-rating-at-cantor-fitzgerald.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply